Endocrine Hypertension Immunoassays

Simple, Fast Aldosterone and Renin Measurements

Our Immunodiagnostic Systems Limited (referred to hereafter as IDS) hypertension panel currently offers fully automated, non-radioactive immunoassays for the measurement of Aldosterone and Direct Renin from the same plasma sample to improve laboratory workflow.

30% of the adult population suffer from hypertension and in 15-20% of these patients it may be due to endocrine causes such as Primary Aldosteronism (PA).  In another 5% of patients the elevated blood pressure is due to Renovascular Hypertension 1,2,3.

In PA excess, aldosterone levels may be produced due to an adenoma (Conn’s syndrome) or hyperplasia 4. Patients with this condition are at a stronger risk of heart disease and stroke than those with essential hypertension 4. PA patients also have higher cardiovascular morbidity and mortality than age and sex-matched patients with essential hypertension. According to the Endocrine Society guidelines, both Renin and Aldosterone need to be measured as an elevated Aldosterone to Renin ratio (ARR) is the screening test indicative for the presence of PA 5. The measurement of Renin itself can also be used to stratify risk in essential hypertension patients.

The fully automated IDS hypertension panel consolidates the testing of Aldosterone and Renin with simple and fast quantitative immunoassay methods.

  • Direct measurement. No extraction needed
  • Fully automated testing process
  • Quick turnaround time between prescription and result
  • Only 1 plasma sample required
  1. Kearney, PM et al., Global burden of Hypertension: analysis of worldwide data. Lancet, 365 (9455): 217-223, 2005.
  2. Rossi, GP et al., Clinical use of laboratory test for the identification of secondary hypertension, Crit Rev Clin Lab Sci, 44: 1-85, 2007.
  3. Mulatero, P. et al., Increased diagnosis of Primary aldosteronism in centers from five continents. J Clin Endocrinol Metab, 89(3): 1045–1050, 2004.
  4. Milliez, P. et al., Evidence for an increased rate of cardiovascular events in patients with primary Aldosteronism. J Am Coll Cardiol, 45 (8): 1243-8, 2005.
  5. Funder, J.W. et al., Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93 (9): 3266-81, 2008.

Endocrine Hypertension Immunoassays

Portfolio Certification Clinical Area Product Type RUO/IVD
Aldosterone

CE Marked
FDA Cleared

Automated IVD
Direct Renin

CE Marked
FDA Cleared

Automated IVD

Search products

Keyword Search

You can use the keyword search to get results based on specific words or phrases relating to your chosen product

Need more information? Get in touch

Fill in the boxes below to get in contact